Kiniksa Pharmaceuticals Files Form 144 for Security Sale
Ticker: KNSA · Form: 144 · Filed: Apr 9, 2026 · CIK: 0001730430
| Field | Detail |
|---|---|
| Company | Kiniksa Pharmaceuticals International, PLC (KNSA) |
| Form Type | 144 |
| Filed Date | Apr 9, 2026 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: insider-filing, securities-sale, form-144
Related Tickers: KNSA
TL;DR
Kiniksa filing 144 - looks like someone's selling shares.
AI Summary
On April 9, 2026, Kiniksa Pharmaceuticals International, plc filed a Form 144, indicating a proposed sale of securities. The filing was made by Michael R. Megna, associated with the company, whose mailing and business address is in London, United Kingdom.
Why It Matters
This filing signals potential insider selling or a planned divestment of shares by an individual associated with Kiniksa Pharmaceuticals, which could impact market perception.
Risk Assessment
Risk Level: medium — Form 144 filings can indicate insider selling, which may precede a price drop, but the specific details and volume are not yet known.
Key Players & Entities
- Kiniksa Pharmaceuticals International, plc (company) — Subject of the filing
- Michael R. Megna (person) — Reporting person
- 0001730430 (company) — CIK for Kiniksa Pharmaceuticals International, plc
- 0001464583 (person) — CIK for Michael R. Megna
FAQ
What is the purpose of a Form 144 filing?
A Form 144 filing is a notice of proposed sale of restricted securities or control securities.
Who is the reporting person in this filing?
Michael R. Megna is listed as the reporting person.
What is the CIK for Kiniksa Pharmaceuticals International, plc?
The CIK for Kiniksa Pharmaceuticals International, plc is 0001730430.
When was this Form 144 filing accepted?
This Form 144 filing was accepted on April 9, 2026.
What is the business address of Kiniksa Pharmaceuticals International, plc?
The business address is 105 PICCADILLY, SECOND FLOOR LONDON United Kingdom W1J 7NJ.
Filing Details
This Form 144 (Form 144) was filed with the SEC on April 9, 2026 by Michael R. Megna regarding Kiniksa Pharmaceuticals International, plc (KNSA).